Skip to content
Sign inOpen the app
Artwork for The Readout Loud
The Readout Loud · June 11 · 36 min

405: An obesity drug deep-dive, and peptides move mainstream

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.

0:00-36:26
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?


We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center).


We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.

more episodes

All episodes